Patients’ baseline characteristics (N = 79)
| Characteristic . | n (%) . |
|---|---|
| Age, y | |
| <60 | 43 (54) |
| ≥60 | 36 (46) |
| Ethnicity | |
| White | 72 (91) |
| Non-white | 5 (6) |
| Unknown | 2 (3) |
| Sex | |
| Female | 39 (49) |
| Male | 40 (51) |
| Hemoglobin, g/dL | |
| ≥12 | 75 (95) |
| <12 | 4 (5) |
| β2-microglobulin | |
| Low-normal | 51/68 (75) |
| Elevated | 17/68 (25) |
| Lactate dehydrogenase | |
| Low-normal | 73/75 (97) |
| Elevated | 2/75 (3) |
| Bone marrow | |
| Not involved | 44 (56) |
| Involved | 35 (44) |
| B symptoms | |
| Absent | 69 (87) |
| Present | 10 (13) |
| Ann Arbor stage | |
| III | 35 (44) |
| IV | 44 (56) |
| Involved nodal areas, n | |
| <5 | 31 (39) |
| ≥5 | 48 (61) |
| Size of largest lymph node, cm | |
| <6 | 71 (90) |
| ≥6 | 8 (10) |
| Extranodal disease | |
| Absent | 50 (63) |
| Present | 29 (37) |
| FLIPI score | |
| Low | 31 (39) |
| Intermediate | 34 (43) |
| High | 14 (18) |
| FLIPI-2 score | |
| Low | 10 (12) |
| Intermediate | 51 (65) |
| High | 18 (23) |
| PRIMA-PI | |
| Low | 42 (53) |
| Intermediate | 32 (41) |
| High | 5 (6) |
| SUVmax | |
| ≤10 | 40/76 (53) |
| >10 | 36/76 (47) |
| Characteristic . | n (%) . |
|---|---|
| Age, y | |
| <60 | 43 (54) |
| ≥60 | 36 (46) |
| Ethnicity | |
| White | 72 (91) |
| Non-white | 5 (6) |
| Unknown | 2 (3) |
| Sex | |
| Female | 39 (49) |
| Male | 40 (51) |
| Hemoglobin, g/dL | |
| ≥12 | 75 (95) |
| <12 | 4 (5) |
| β2-microglobulin | |
| Low-normal | 51/68 (75) |
| Elevated | 17/68 (25) |
| Lactate dehydrogenase | |
| Low-normal | 73/75 (97) |
| Elevated | 2/75 (3) |
| Bone marrow | |
| Not involved | 44 (56) |
| Involved | 35 (44) |
| B symptoms | |
| Absent | 69 (87) |
| Present | 10 (13) |
| Ann Arbor stage | |
| III | 35 (44) |
| IV | 44 (56) |
| Involved nodal areas, n | |
| <5 | 31 (39) |
| ≥5 | 48 (61) |
| Size of largest lymph node, cm | |
| <6 | 71 (90) |
| ≥6 | 8 (10) |
| Extranodal disease | |
| Absent | 50 (63) |
| Present | 29 (37) |
| FLIPI score | |
| Low | 31 (39) |
| Intermediate | 34 (43) |
| High | 14 (18) |
| FLIPI-2 score | |
| Low | 10 (12) |
| Intermediate | 51 (65) |
| High | 18 (23) |
| PRIMA-PI | |
| Low | 42 (53) |
| Intermediate | 32 (41) |
| High | 5 (6) |
| SUVmax | |
| ≤10 | 40/76 (53) |
| >10 | 36/76 (47) |
All patients had low-grade FL (grade 1-2); Ki67 was assessed in 18 patients, and it was ≥40% in 3 (17%).